MorphoSys AG
Treatment for rheumatoid arthritis
Last updated:
Abstract:
The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
Status:
Grant
Type:
Utility
Filling date:
26 Jan 2018
Issue date:
9 Feb 2021